Crispr Therapeutics Ag (CRSP)

R&D to Revenue

637.97%

Quarterly · Period ending:

CRSP logo

CRSP R&D to Revenue

Latest reported637.97%
CRSP Quarterly R&D/Revenue (0.00% → 637.97%)
High-resolution chart · PNG

CRSP r&d to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Crispr Therapeutics Ag R&D to Revenue — Quarterly
Period endingR&D to Revenue
637.9727%
4,703.2922%
9,012.1528%
6,625.6468%
7,319.9552%
8,379.6532%
234.7286%
12,850.4983%
14,568.6654%
14,154.5635%
47.572%
0%
145.0786%
99.935%
1,725,916.6667%
124,065.9574%
77,989.2405%
66,429.7753%
799.248%
25,379.9392%
9.1459%
34,960.396%
22,260.8108%
47,978.3784%
134,954.5455%
34,517.8344%
63.3128%
27.012%
12,431.761%
10,311.5854%
25,044.3478%
7,072.8242%
2,355.9743%
1,437.3343%
61.9644%
747.5911%
477.9453%
547.7248%
664.3345%
778.0504%
1,082.0126%
1,263.0252%
2,499.5951%
0%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.